Cargando…

Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers

BACKGROUND: Hydroxyurea (HU) is an hemoglobin F inducing agent used in the treatment of sickle cell disease (SCD). AIM: The aim of this study is to determine the perception of HU by people living with SCD. MATERIALS AND METHODS: A pretested questionnaire was self-administered to known cases of SCD a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korubo, Kaladada I., Onodingene, Nkemsinachi Maryanne, Okoye, Helen Chioma, Omunakwe, Hannah E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378460/ https://www.ncbi.nlm.nih.gov/pubmed/34213480 http://dx.doi.org/10.4103/aam.aam_36_20

Ejemplares similares

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
por: Korubo, Kaladada I., et al.
Publicado: (2017)

Erratum: Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
Publicado: (2021)

Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria
por: Madu, Anazoeze Jude, et al.
Publicado: (2019)

Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center
por: Korubo, Kaladada Ibitrokoemi, et al.
Publicado: (2021)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults
por: Badawy, Sherif M., et al.
Publicado: (2017)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
por: Pandey, Akancha, et al.
Publicado: (2023)

Response to Hydroxyurea in a Patient With Sickle Cell Hepatopathy: A Case Report
por: Safhi, Maha A, et al.
Publicado: (2021)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
por: Creary, Susan, et al.
Publicado: (2015)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
por: Dhar, Arushi, et al.
Publicado: (2021)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
por: Yadav, Dhiraj Kumar, et al.
Publicado: (2020)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria
por: Isa, Hezekiah Alkali, et al.
Publicado: (2022)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries
por: Mulaku, Mercy, et al.
Publicado: (2013)

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease
por: de Araujo, Olinda Maria Rodrigues, et al.
Publicado: (2015)

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
por: Mnika, Khuthala, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cdadq9vo1lanb05nf8aqq524jo